Does insulin preserve β-cell function in type 2 diabetes?

Journal of Internal Medicine

Volumn 251, Issue 4, 2002, Pages 283-285

  Heise, T ^a   Sawicki, Peter T ^a  

^a St Franziskus Hospital Koln   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; C PEPTIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

CELL FUNCTION; DIET RESTRICTION; DRUG EFFECT; EDITORIAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; QUALITY OF LIFE;

CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; SULFONYLUREA COMPOUNDS;

EID: 0036272043     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2002.00965.x     Document Type: Editorial

References (16)

1. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled, double-blind trial
2. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
3. The medical management of hyperglycemia over a 10-year period in people with diabetes
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
5. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects
6. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
7. United Kingdom Prospective Diabetes Study 24. A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy
8. Beta-cell apoptosis, stimuli and signaling
9. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM
10. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by intensive insulin treatment
11. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients
12. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
13. A rapid increase in β-cell function by multiple insulin injections in type 2 diabetic patients in not further enhanced by prolonging treatment
14. Reproducibility of beta-cell function estimates in non-insulin-dependent diabetes mellitus
15. UKPDS 25: Autoanti-bodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
16. Insulin treatment with preprandial injections of regular insulin in middle-aged type 2 diabetic patients. A two years observational study